Search

How to apply for an EHA Bilateral Collaborative Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Bilateral Collaborative Grant application.

Read more

Highlights from the SWG

The European Scientific foundation for Laboratory Hemato Oncology (ESLHO), together with the three scientific consortia of EuroClonality, EuroMRD, and EuroFlow, share the same four goals:

Research and innovation of diagnostic patient care
Standardization of laboratory diagnostics
Quality assessment
Education
ESLHO supports the three consortia in…

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more

Burnout - it doesn't just happen to someone else

Burnout - it doesn't just happen to someone else

By Dr. med.

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Board elections

Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.

Read more